----item----
version: 1
id: {6C930B4A-1B37-499A-AB3F-5718E3EC07CA}
database: master
path: /sitecore/content/ScripIntelligence/Home/Articles/2015/05/29/FDA deems SanofiGenzyme drug olipudase alfa breakthrough
parent: {9E44CD89-5CEF-43CD-B8D5-C3B05FCA838C}
name: FDA deems SanofiGenzyme drug olipudase alfa breakthrough
master: {00000000-0000-0000-0000-000000000000}
template: {11380B5D-3531-4570-B213-EFC5312266E4}
templatekey: Article

----version----
language: en
version: 1
revision: 3941e84f-21c7-4d50-94ba-a3c6f660efa5

----field----
field: {0212FC0F-953B-461C-B4D9-B7483A4D4F1B}
name: Taxonomy
key: taxonomy
content-length: 77

{8B2376D2-D914-41D6-9402-D3CD38CABF23}|{3A5E806F-C17B-4751-9A9A-7717F936EE6A}
----field----
field: {2D750EFF-9058-4ABF-A7FF-57FFE5DA1E3C}
name: Title
key: title
content-length: 59

FDA deems Sanofi/Genzyme drug olipudase alfa 'breakthrough'
----field----
field: {F1D1DC93-63DF-4AFA-B60F-B3A3E9D36675}
name: Sub Title
key: sub title
content-length: 56

FDA deems SanofiGenzyme drug olipudase alfa breakthrough
----field----
field: {446A339B-E1D9-4DE1-8B5E-DB7942EF1723}
name: Body
key: body
content-length: 1753

<p>The FDA has granted breakthrough therapy designation (BTD) to an experimental medicine from Sanofi and its US Genzyme unit for olipudase alfa, an experimental enzyme replacement therapy being investigated to treat Niemann-Pick disease type B (NPB).</p><p>NPB is a serious and life-threatening disorder caused by insufficient activity of the enzyme acid sphingomyelinase, which results in toxic accumulation of sphingomyelin. </p><p>There currently are no FDA-approved treatments for NPB. </p><p>"We are hopeful that olipudase alfa can be developed into a meaningful treatment for patients," said Dr Richard Peters, global head of rare diseases at Genzyme. </p><p>To <a href="http://www.scripintelligence.com/home/US-Capitol-Capsule-Breakthrough-fees-FDA-urges-self-control-on-requests-358065" target="_new">gain the BTD</a>, which was <a href="http://www.scripintelligence.com/home/All-too-easy-Obama-signs-US-FDA-user-fee-bill-without-fanfare-332602" target="_new">created</a> the <i>Food and Drug Administration Safety and Innovation Act</i>, a drug must be intended to treat a serious condition and have preliminary clinical evidence that indicates the medicine may demonstrate substantial improvement on at least one clinically significant endpoint over available therapies.</p><p>As of 29 May &ndash; the most recent date for which data are available &ndash; the FDA's Center for Drug Evaluation and Research had granted at least 78 of the 258 requests for BTD it has received since July 2012, with regulators denying at least 132.</p><p>As of 31 May, the FDA's Center for Biologics Evaluation and Research had granted at least 12 of the 50 requests it has received for breakthrough status, denying at least 37.</p><p><p><p><p><p><p><p><p><p><p>
----field----
field: {5BA0578F-65B7-4C22-8233-1603D698D8A4}
name: Summary
key: summary
content-length: 255

<p>The FDA has granted breakthrough therapy designation (BTD) to an experimental medicine from Sanofi and its US Genzyme unit for olipudase alfa, an experimental enzyme replacement therapy being investigated to treat Niemann-Pick disease type B (NPB).</p>
----field----
field: {8F4EE718-6FA0-42A5-85C4-6C8FE8B1FCD4}
name: Navigation Title
key: navigation title
content-length: 56

FDA deems SanofiGenzyme drug olipudase alfa breakthrough
----field----
field: {7C4FC796-1311-4DAA-81AC-85EAA2C1C108}
name: Actual Publish Date
key: actual publish date
content-length: 15

20150529T160003
----field----
field: {BDF7C8E1-869E-49FF-B9F5-854B3081A45D}
name: Created Date
key: created date
content-length: 15

20150529T160003
----field----
field: {C926A72A-39DA-446D-B78C-2A650F820A73}
name: Modified Date
key: modified date
content-length: 15

20150529T160003
----field----
field: {1616FE67-7278-4169-948E-C29B00EC8781}
name: Article Number
key: article number
content-length: 8

SC028912
----field----
field: {31603F25-6D9C-4954-BCDE-342E1E184A30}
name: Meta Title Override
key: meta title override
content-length: 59

FDA deems Sanofi/Genzyme drug olipudase alfa 'breakthrough'
----field----
field: {5AD65E47-7554-4CE5-87B0-7FB65051C05A}
name: Authors
key: authors
content-length: 38

{185C14A2-61E1-460C-96C2-EB0D8AB963B0}
----field----
field: {AE1BD751-D4E7-49CB-96C4-62E995A06B51}
name: Article Category
key: article category
content-length: 4

news
----field----
field: {0F6C8F42-01DC-4E05-B63E-AA25D8AA0E09}
name: Legacy Publication
key: legacy publication
content-length: 38

{0F9CCE10-91C1-4F31-832A-266F482A5DAF}
----field----
field: {5795FF15-0942-41FF-8A77-3B73185F5E1B}
name: Escenic ID
key: escenic id
content-length: 6

358661
----field----
field: {25BED78C-4957-4165-998A-CA1B52F67497}
name: __Created
key: __created
content-length: 16

20160209T042357Z
----field----
field: {5DD74568-4D4B-44C1-B513-0AF5F4CDA34F}
name: __Created by
key: __created by
content-length: 18

sitecore\Anonymous
----field----
field: {8CDC337E-A112-42FB-BBB4-4143751E123F}
name: __Revision
key: __revision
content-length: 36

3941e84f-21c7-4d50-94ba-a3c6f660efa5
----field----
field: {D9CF14B1-FA16-4BA6-9288-E8A174D4D522}
name: __Updated
key: __updated
content-length: 16

20160209T042357Z
----field----
field: {BADD9CF9-53E0-4D0C-BCC0-2D784C282F6A}
name: __Updated by
key: __updated by
content-length: 18

sitecore\Anonymous
